Zim Laboratories Limited — Investor Meet, 26-05-2025: Analysts/Institutional Investor Meet/Con. Call Updates

ZIM Laboratories reported Q4 revenue of INR 109 crore, up 13% QoQ but down 8% YoY, with EBITDA margin rising to 15% and PAT margin at 4.5%. FY25 revenue grew 3.2% YoY to INR 379 crore, supported by 75% pharma and 25% nutraceutical sales; exports made up 83%. Innovation-led products (NIP and Oral Thin Films) contributed 16.5% of revenue, driven by licensing in regulated markets. Management expects commercial launches in Europe, Australia, and the Middle East from Q3 FY26. CapEx of INR 36.5 crore expanded capacity, with R&D spend steady at 8.8% of revenue. Despite legacy business headwinds, management is confident of 25%-30% CAGR over 2-3 years, margin expansion, and growth via global partnerships and regulated market scaling.